Literature DB >> 17431533

Glomerular filtration rate is a major determinant of the relationship between 25-hydroxyvitamin D and parathyroid hormone.

S Patel1, S Hyer, J Barron.   

Abstract

The reference range for 25-hydroxyvitamin D (25-OHD) remains uncertain, and it is not clear as to whether interpretation of circulating 25-OHD would be aided by simultaneous measurement of serum parathyroid hormone (PTH). We wanted to define the level of serum 25-OHD associated with a raised serum PTH and to examine the determinants of the relationship between serum 25-OHD and serum PTH concentration. We retrospectively examined data for patients who had a 25-OHD measurement and other biochemical variables over a 12-month period in our center. We found that 28% of patients had a serum 25-OHD level below 50 nmol/L and serum PTH level in the normal reference range, whereas 24% had a serum 25-OHD level below 50 nmol/L with a serum PTH value above the normal reference range. At a serum 25-OHD level of 80 nmol/L, 1.5% had an elevated serum PTH and, at 50 nmol/L, 8% had raised serum PTH. Further examination showed that for patients with low serum 25-OHD, low glomerular filtration rate (GFR) was a major determinant of the PTH response. These data confirm an inverse correlation between serum 25-OHD and serum PTH. Minimal numbers of patients (1.5% of the study group) have a raised serum PTH at a serum 25-OHD level of 80 nmol/L. GFR is a major determinant of the PTH response to decreasing serum levels of 25-OHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17431533     DOI: 10.1007/s00223-007-9001-9

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  8 in total

1.  Changes in bone mineral parameters, vitamin D metabolites, and PTH measurements with varying chronic kidney disease stages.

Authors:  Sanjeev Patel; Jeffrey L Barron; Mehdi Mirzazedeh; Hugh Gallagher; Steve Hyer; Tom Cantor; William D Fraser
Journal:  J Bone Miner Metab       Date:  2010-06-03       Impact factor: 2.626

2.  Serum 25-hydroxyvitamin D, parathyroid hormone, calcium intake, and bone mineral density in Spanish adults.

Authors:  J M Olmos; J L Hernández; P García-Velasco; J Martínez; J Llorca; J González-Macías
Journal:  Osteoporos Int       Date:  2015-07-02       Impact factor: 4.507

3.  Proceedings of the Rank Forum on Vitamin D.

Authors:  S A Lanham-New; J L Buttriss; L M Miles; M Ashwell; J L Berry; B J Boucher; K D Cashman; C Cooper; A L Darling; R M Francis; W D Fraser; C P G M de Groot; E Hyppönen; M Kiely; C Lamberg-Allardt; H M Macdonald; A R Martineau; T Masud; A Mavroeidi; C Nowson; A Prentice; E M Stone; S Reddy; R Vieth; C M Williams
Journal:  Br J Nutr       Date:  2010-12-07       Impact factor: 3.718

4.  Parathyroid Gland Response to Vitamin D Deficiency in Type 2 Diabetes Mellitus: An Observational Study.

Authors:  Azhar Hussain; Omar B Latiwesh; Alia Ali; Elsa Tabrez; Lalit Mehra; Fidelis Nwachukwu
Journal:  Cureus       Date:  2018-11-28

5.  High prevalence of hypovitaminosis D and secondary hyperparathyroidism in elders living in nonprofit homes in South Brazil.

Authors:  Rosana Scalco; Melissa O Premaor; Pedro E Fröehlich; Tania W Furlanetto
Journal:  Endocrine       Date:  2008-04-10       Impact factor: 3.633

6.  Hypovitaminosis D and secondary hyperparathyroidism in resident physicians of a general hospital in southern Brazil.

Authors:  M O Premaor; P Paludo; D Manica; A P Paludo; E R Rossatto; R Scalco; T W Furlanetto
Journal:  J Endocrinol Invest       Date:  2008-11       Impact factor: 4.256

7.  Parathyroid Glands response to Low Vitamin D levels in Healthy Adults: A Cross-Sectional Study.

Authors:  Mir Sadat-Ali; Abdullah S Al-Omran; Haifa A Al-Turki
Journal:  Ulster Med J       Date:  2015-01

8.  Vitamin D supplementation in older people (VDOP): Study protocol for a randomised controlled intervention trial with monthly oral dosing with 12,000 IU, 24,000 IU or 48,000 IU of vitamin D₃.

Authors:  Inez Schoenmakers; Roger M Francis; Elaine McColl; Thomas Chadwick; Gail R Goldberg; Christine Harle; Alison Yarnall; Jennifer Wilkinson; Jennie Parker; Ann Prentice; Terence Aspray
Journal:  Trials       Date:  2013-09-17       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.